Microbiome Report for Week Ending 11/24/18

Microbiome Report for Week Ending 11/24/18

Source: 
CP Wire
snippet: 

Infant Bacterial Therapeutics Modifies Ph III Protocol After Meeting with FDA

Following its meeting with the US Food and Drug Administration (FDA) in Washington DC to discuss the design of the company’s clinical development program, IBT has chosen to modify its Phase III study of IBP-9414 for the prevention of necrotizing enterocolitis (NEC) in premature infants.